Citi sets PharmaResearch stock Buy rating, KRW560,000 target

Published 19/05/2025, 17:06
Citi sets PharmaResearch stock Buy rating, KRW560,000 target

On Monday, Citi initiated coverage on PharmaResearch Co Ltd (214450:KS), a South Korean biopharmaceutical company, with a Buy rating and a KRW560,000 price target. The new price target suggests a positive outlook for the company’s financial growth.

Analysts at Citi have highlighted PharmaResearch’s unique brand originality as a key driver for the company’s expected revenue growth. They anticipate that the company will see an expansion in sales due to several factors. First, there is projected structural growth within the domestic market, supported by ongoing favorable trends. Additionally, there is strong demand from European and U.S. markets, which is anticipated to boost the company’s momentum as it enters new markets.

PharmaResearch’s strategic approach to sales, which involves bundling toxin, skin booster, and energy-based devices, is also expected to contribute to its medium-term sales growth. This strategy aligns with the company’s overall growth trajectory and is seen as a positive move by Citi’s analysts.

The endorsement from Citi comes as PharmaResearch continues to make strides in the biopharmaceutical industry. The company’s focus on developing original products and expanding its global footprint is central to its growth strategy.

Investors and market watchers will likely keep a close eye on PharmaResearch’s performance in the coming months, as the company works to meet the expectations set forth by Citi’s coverage initiation. The company’s stock performance and ability to capitalize on the opportunities outlined by Citi will be of particular interest to those following the biopharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.